It was a pleasure to present at the Open Innovation in Pharmaceutical R&D conference last week in Amsterdam. What strikes me in conferences like this is the diversity of ways open innovation is manifested. While some seem to criticize that “everything is now open innovation”, I’ve come to appreciate the diversity. To me it isn’t about what it is called, but rather what it accomplishes.
While diversity of approaches exist, it still seems to me that the focus of OI in pharma R&D remains in research, not development. As I outline in my presentation, I believe there is not only a position for OI in development but an essential need to change, and yes, disrupt our business model. Contrary to gut reactions, this is NOT a challenge to the current IP/patent centric model. In fact, it depends on clear IP and the patent foundation coming into provides a clear platform on which OI can operate. In the same manner, clear commons licensing enables collaborative interaction around public information.
Ours is a strategy of raising all boats and helping transform the industry models of clinical development. We welcome the diversity of ideas and implementation models. For it won’t be one company, one model, or one frame of reference that will change our current, well-entrenched business model. It will be through creative, collaborative efforts that new models for development emerge. This is why we think of our work as a series of experiments or projects. Have ideas and an interest in working with us? Drop us a note and let’s figure out how we can be complementary. The patient is waiting.